We’re experiencing issues for some mobile devices with our ARTG dataset filter function. We apologise for any inconvenience while we work to fix this.
CIPLA TEDUGLUTIDE (Cipla Australia Pty Ltd)
Product name
CIPLA TEDUGLUTIDE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
193 (255 working days)
Active ingredients
teduglutide
Registration type
NCE/NBE
Indication
TRADE NAME is indicated for the treatment of adult and paediatric patients 2 years of age and above with Short Bowel Syndrome (SBS) who are dependent on parenteral support. Patients should be stable for at least 4 weeks on their parenteral support regimen before initiating teduglutide therapy.